Pamidronate disodium salt hydrate, >=95% (NMR), solid

Pamidronate disodium salt hydrate, >=95% (NMR), solid

Biochem/physiol Actions

Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC50 = 200 nM).

Pamidronate disodiumhas the ability to block Wnt and ?-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

10, 100 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level mp InChI key InChI Manufacturer Form Assay Price Quantity
3573526 Pamidronate disodium salt hydrate, >=95% (NMR), solid white 100 300 °C TVQNUQCYOOJTMK-UHFFFAOYSA-L
£711.75 (exc VAT) per 100MG
-
+
3573527 Pamidronate disodium salt hydrate, >=95% (NMR), solid white 100 300 °C TVQNUQCYOOJTMK-UHFFFAOYSA-L
£154.61 (exc VAT) per 10MG
-
+